Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Biotechnology Company Showcases OLC Bioequivalence Data

OLC represents a next-generation leap in the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD).
Unicycive Therapeutics, Inc., a clinical-stage biotechnology firm dedicated to improving the lives of patients with kidney disease, recently made strides in showcasing its innovative capabilities at the National Kidney Foundation (NKF) Spring Clinical Meeting. The company's lead product candidate, oxylanthanum carbonate (OLC), took center stage as promising bioequivalence data was presented, underscoring Unicycive’s commitment to advancing kidney disease treatment. $Unicycive Therapeutics(UNCY.US)$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
1030 Views
Comment
Sign in to post a comment
    142Followers
    0Following
    326Visitors
    Follow